Download PDF
Semin Respir Crit Care Med 2021; 42(03): 471-482
DOI: 10.1055/s-0041-1729173
Review Article

Fungal Infection in Lung Transplantation

Cassie C. Kennedy
1   Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota
2   William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota
,
Kelly M. Pennington
1   Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota
2   William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota
,
Elena Beam
2   William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota
3   Division of Infectious Disease, Mayo Clinic, Rochester, Minnesota
,
Raymund R. Razonable
2   William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota
3   Division of Infectious Disease, Mayo Clinic, Rochester, Minnesota
› Author Affiliations Funding C.C.K. is funded in part by National Institute of Health (NIH) HL 128859. The manuscript's contents are solely the responsibility of the authors and do not necessarily represent the official view of the NIH.
› Further Information
   Permissions and Reprints

Abstract

Invasive fungal infections threaten lung transplant outcomes with high associated morbidity and mortality. Pharmacologic prophylaxis may be key to prevent posttransplant invasive fungal infections, but cost, adverse effects, and absorption issues are barriers to effective prophylaxis. Trends in fungal infection diagnostic strategies utilize molecular diagnostic methodologies to complement traditional histopathology and culture techniques. While lung transplant recipients are susceptible to a variety of fungal pathogens, Candida spp. and Aspergillus spp. infections remain the most common. With emerging resistant organisms and multiple novel antifungal agents in the research pipeline, it is likely that treatment strategies will continue to evolve.

Keywords

lung transplant - fungal infection - immunocompromised - antifungal prophylaxis


Publication History

Article published online:
24 May 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Arthurs SK, Eid AJ, Deziel PJ. et al. The impact of invasive fungal diseases on survival after lung transplantation. Clin Transplant 2010; 24 (03) 341-348
    CrossrefPubMedGoogle Scholar
  • 2 Bhaskaran A, Mumtaz K, Husain S. Anti-Aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis. Curr Infect Dis Rep 2013; 15 (06) 514-525
    CrossrefPubMedGoogle Scholar
  • 3 Cornely OA, Hoenigl M, Lass-Flörl C. et al; Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM). Defining breakthrough invasive fungal infection—position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses 2019; 62 (09) 716-729
    CrossrefPubMedGoogle Scholar
  • 4 Doligalski CT, Benedict K, Cleveland AA. et al. Epidemiology of invasive mold infections in lung transplant recipients. Am J Transplant 2014; 14 (06) 1328-1333
    CrossrefPubMedGoogle Scholar
  • 5 Vazquez R, Vazquez-Guillamet MC, Suarez J, Mooney J, Montoya JG, Dhillon GS. Invasive mold infections in lung and heart-lung transplant recipients: Stanford University experience. Transpl Infect Dis 2015; 17 (02) 259-266
    CrossrefPubMedGoogle Scholar
  • 6 Ashraf N, Kubat RC, Poplin V. et al. Re-drawing the maps for endemic mycoses. Mycopathologia 2020; 185 (05) 843-865
    CrossrefPubMedGoogle Scholar
  • 7 Maphanga TG, Birkhead M, Muñoz JF. et al. Human blastomycosis in South Africa caused by Blastomyces percursus and Blastomyces emzantsi sp. nov., 1967 to 2014. J Clin Microbiol 2020; 58 (03) 58
    CrossrefPubMedGoogle Scholar
  • 8 Oltean HN, Springer M, Bowers JR. et al. Suspected locally acquired coccidioidomycosis in human, Spokane, Washington, USA. Emerg Infect Dis 2020; 26 (03) 606-609
    CrossrefPubMedGoogle Scholar
  • 9 Lestrade PPA, Buil JB, van der Beek MT. et al. Paradoxal trends in azole-resistant Aspergillus fumigatus in a national multicenter surveillance program, the Netherlands, 2013-2018. Emerg Infect Dis 2020; 26 (07) 1447-1455
    CrossrefPubMedGoogle Scholar
  • 10 Zhang J, Lopez Jimenez L, Snelders E. et al. Dynamics of Aspergillus fumigatus in azole fungicide-containing plant waste in the Netherlands (2016-2017). Appl Environ Microbiol 2021; 87 (02) e02295-e20
    CrossrefPubMedGoogle Scholar
  • 11 Baddley JW, Marr KA, Andes DR. et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47 (10) 3271-3275
    CrossrefPubMedGoogle Scholar
  • 12 Delbove A, Alami H, Tissot A. et al. Pneumocystis pneumonia after lung transplantation: a retrospective multicenter study. Respir Med 2020; 169: 106019
    CrossrefPubMedGoogle Scholar
  • 13 Neoh CF, Snell GI, Kotsimbos T. et al. Antifungal prophylaxis in lung transplantation--a world-wide survey. Am J Transplant 2011; 11 (02) 361-366
    CrossrefPubMedGoogle Scholar
  • 14 Pennington KM, Yost KJ, Escalante P, Razonable RR, Kennedy CC. Antifungal prophylaxis in lung transplant: a survey of United States' transplant centers. Clin Transplant 2019; 33 (07) e13630
    CrossrefPubMedGoogle Scholar
  • 15 Pennington KM, Baqir M, Erwin PJ, Razonable RR, Murad MH, Kennedy CC. Antifungal prophylaxis in lung transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis 2020; 22 (04) e13333
    CrossrefPubMedGoogle Scholar
  • 16 Pennington KM, Razonable RR, Peters S. et al. Why do lung transplant patients discontinue triazole prophylaxis?. Transpl Infect Dis 2019; 21 (03) e13067
    CrossrefPubMedGoogle Scholar
  • 17 Pennington KM, Dykhoff HJ, Yao X. et al. The impact of antifungal prophylaxis in lung transplant recipients. Ann Am Thorac Soc 2021; 18 (03) 468-476
    CrossrefPubMedGoogle Scholar
  • 18 Neoh CF, Snell GI, Levvey B. et al. Preemptive treatment with voriconazole in lung transplant recipients. Transpl Infect Dis 2013; 15 (04) 344-353
    CrossrefPubMedGoogle Scholar
  • 19 Pilarczyk K, Haake N, Heckmann J. et al. Is universal antifungal prophylaxis mandatory in adults after lung transplantation? A review and meta-analysis of observational studies. Clin Transplant 2016; 30 (12) 1522-1531
    CrossrefPubMedGoogle Scholar
  • 20 Lass-Flörl C, Aigner M, Nachbaur D. et al. Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience. Infection 2017; 45 (06) 867-875
    CrossrefPubMedGoogle Scholar
  • 21 Bart-Delabesse E, Basile M, Al Jijakli A. et al. Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments. J Clin Microbiol 2005; 43 (10) 5214-5220
    CrossrefPubMedGoogle Scholar
  • 22 Castagnola E, Machetti M, Bucci B, Viscoli C. Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect 2004; 10 (Suppl. 01) 86-95
    CrossrefPubMedGoogle Scholar
  • 23 Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42 (10) 1417-1427
    CrossrefPubMedGoogle Scholar
  • 24 Park SY, Lee SO, Choi SH. et al. Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect 2010; 61 (06) 492-498
    CrossrefPubMedGoogle Scholar
  • 25 Bergeron A, Belle A, Sulahian A. et al. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 2010; 137 (02) 410-415
    CrossrefPubMedGoogle Scholar
  • 26 Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010; 138 (04) 817-824
    CrossrefPubMedGoogle Scholar
  • 27 Heng SC, Morrissey O, Chen SC. et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol 2015; 41 (01) 124-134
    CrossrefPubMedGoogle Scholar
  • 28 Luong ML, Filion C, Labbé AC. et al. Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies. Diagn Microbiol Infect Dis 2010; 68 (02) 132-139
    CrossrefPubMedGoogle Scholar
  • 29 Racil Z, Kocmanova I, Toskova M. et al. Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. Int J Infect Dis 2011; 15 (12) e874-e881
    CrossrefPubMedGoogle Scholar
  • 30 Nucci M, Carlesse F, Cappellano P. et al. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS One 2014; 9 (01) e87784
    CrossrefPubMedGoogle Scholar
  • 31 Busca A, Locatelli F, Barbui A. et al. Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc 2006; 38 (05) 1610-1613
    CrossrefPubMedGoogle Scholar
  • 32 Obayashi T, Yoshida M, Mori T. et al. Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345 (8941): 17-20
    CrossrefPubMedGoogle Scholar
  • 33 Hage CA, Carmona EM, Evans SE, Limper AH, Ruminjo J, Thomson CC. Summary for clinicians: microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice. Ann Am Thorac Soc 2019; 16 (12) 1473-1477
    CrossrefPubMedGoogle Scholar
  • 34 Bansal N, Gopalakrishnan R, Sethuraman N. et al. Experience with β-D-glucan assay in the management of critically ill patients with high risk of invasive candidiasis: an observational study. Indian J Crit Care Med 2018; 22 (05) 364-368
    CrossrefPubMedGoogle Scholar
  • 35 Posteraro B, Tumbarello M, De Pascale G. et al. (1,3)-β-D-glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. J Antimicrob Chemother 2016; 71 (08) 2262-2269
    CrossrefPubMedGoogle Scholar
  • 36 Tran T, Beal SG. Application of the 1,3-β-D-glucan (Fungitell) assay in the diagnosis of invasive fungal infections. Arch Pathol Lab Med 2016; 140 (02) 181-185
    CrossrefPubMedGoogle Scholar
  • 37 Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS 2013; 27 (06) 967-972
    CrossrefPubMedGoogle Scholar
  • 38 Cruciani M, Mengoli C, Loeffler J. et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev 2015; CD009551
    PubMedGoogle Scholar
  • 39 Springer J, Goldenberger D, Schmidt F. et al. Development and application of two independent real-time PCR assays to detect clinically relevant Mucorales species. J Med Microbiol 2016; 65 (03) 227-234
    CrossrefPubMedGoogle Scholar
  • 40 Avni T, Levy I, Sprecher H, Yahav D, Leibovici L, Paul M. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. J Clin Microbiol 2012; 50 (11) 3652-3658
    CrossrefPubMedGoogle Scholar
  • 41 Neely LA, Audeh M, Phung NA. et al. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med 2013; 5 (182) 182ra54
    CrossrefPubMedGoogle Scholar
  • 42 Mylonakis E, Clancy CJ, Ostrosky-Zeichner L. et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60 (06) 892-899
    CrossrefPubMedGoogle Scholar
  • 43 Clancy CJ, Nguyen MH. Diagnosing invasive candidiasis. J Clin Microbiol 2018; 56 (05) e01909-e01917
    CrossrefPubMedGoogle Scholar
  • 44 Walker B, Powers-Fletcher MV, Schmidt RL, Hanson KE. Cost-effectiveness analysis of multiplex PCR with magnetic resonance detection versus empiric or blood culture-directed therapy for management of suspected candidemia. J Clin Microbiol 2016; 54 (03) 718-726
    CrossrefPubMedGoogle Scholar
  • 45 Durkin M, Witt J, Lemonte A, Wheat B, Connolly P. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol 2004; 42 (10) 4873-4875
    CrossrefPubMedGoogle Scholar
  • 46 Bariola JR, Hage CA, Durkin M. et al. Detection of Blastomyces dermatitidis antigen in patients with newly diagnosed blastomycosis. Diagn Microbiol Infect Dis 2011; 69 (02) 187-191
    CrossrefPubMedGoogle Scholar
  • 47 Frost HM, Novicki TJ. Blastomyces antigen detection for diagnosis and management of blastomycosis. J Clin Microbiol 2015; 53 (11) 3660-3662
    CrossrefPubMedGoogle Scholar
  • 48 Fandiño-Devia E, Rodríguez-Echeverri C, Cardona-Arias J, Gonzalez A. Antigen Detection in the Diagnosis of Histoplasmosis: A Meta-analysis of Diagnostic Performance. Mycopathologia 2016; 181 (3-4): 197-205
    CrossrefPubMedGoogle Scholar
  • 49 Richer SM, Smedema ML, Durkin MM. et al. Improved diagnosis of acute pulmonary histoplasmosis by combining antigen and antibody detection. Clin Infect Dis 2016; 62 (07) 896-902
    CrossrefPubMedGoogle Scholar
  • 50 Klein BS, Vergeront JM, Weeks RJ. et al. Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. N Engl J Med 1986; 314 (09) 529-534
    CrossrefPubMedGoogle Scholar
  • 51 Richer SM, Smedema ML, Durkin MM. et al. Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using Blastomyces dermatitidis surface protein BAD-1. Clin Vaccine Immunol 2014; 21 (02) 143-146
    CrossrefPubMedGoogle Scholar
  • 52 Malo J, Holbrook E, Zangeneh T. et al. Enhanced antibody detection and diagnosis of coccidioidomycosis with the Miravista IgG and IgM detection enzyme immunoassay. J Clin Microbiol 2017; 55 (03) 893-901
    CrossrefPubMedGoogle Scholar
  • 53 Lortholary O, Renaudat C, Sitbon K. et al; French Mycosis Study Group. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med 2014; 40 (09) 1303-1312
    CrossrefPubMedGoogle Scholar
  • 54 Andes DR, Safdar N, Baddley JW. et al; Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54 (08) 1110-1122
    CrossrefPubMedGoogle Scholar
  • 55 Chamilos G, Luna M, Lewis RE. et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91 (07) 986-989
    PubMedGoogle Scholar
  • 56 Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) 2011; 90 (01) 69-80
    CrossrefPubMedGoogle Scholar
  • 57 Roden MM, Zaoutis TE, Buchanan WL. et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41 (05) 634-653
    CrossrefPubMedGoogle Scholar
  • 58 Stewart JI, D'Alonzo GE, Ciccolella DE, Patel NB, Durra H, Clauss HE. Reverse halo sign on chest imaging in a renal transplant recipient. Transpl Infect Dis 2014; 16 (01) 115-118
    CrossrefPubMedGoogle Scholar
  • 59 Wand O, Unterman A, Izhakian S, Fridel L, Kramer MR. Mucormycosis in lung transplant recipients: a systematic review of the literature and a case series. Clin Transplant 2020; 34 (02) e13774
    CrossrefPubMedGoogle Scholar
  • 60 Marek C, Croxen MA, Dingle TC. et al. The use of genome sequencing to investigate an outbreak of hospital-acquired mucormycosis in transplant patients. Transpl Infect Dis 2019; 21 (05) e13163
    CrossrefPubMedGoogle Scholar
  • 61 Chaves MS, Franco D, Nanni JC. et al. Control of an outbreak of postoperative bone mucormycosis: an intervention study of contiguous cohorts. Am J Infect Control 2016; 44 (12) 1715-1717
    CrossrefPubMedGoogle Scholar
  • 62 Walther G, Wagner L, Kurzai O. Outbreaks of Mucorales and the species involved. Mycopathologia 2020; 185 (05) 765-781
    PubMedGoogle Scholar
  • 63 Limper AH, Knox KS, Sarosi GA. et al; American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183 (01) 96-128
    CrossrefPubMedGoogle Scholar
  • 64 Miller R, Assi M. AST Infectious Diseases Community of Practice. Endemic fungal infections in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33 (09) e13553
    CrossrefPubMedGoogle Scholar
  • 65 Kauffman CA, Freifeld AG, Andes DR. et al. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis 2014; 16 (02) 213-224
    CrossrefPubMedGoogle Scholar
  • 66 Thomas Jr CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350 (24) 2487-2498
    CrossrefPubMedGoogle Scholar
  • 67 Wieruszewski PM, Barreto EF, Barreto JN. et al. Preadmission corticosteroid therapy and the risk of respiratory failure in adults without HIV presenting with Pneumocystis pneumonia. J Intensive Care Med 2020; 35 (12) 1465-1470
    CrossrefPubMedGoogle Scholar
  • 68 Nield B, Larsen SR, van Hal SJ. Clinical experience with new formulation SUBA®-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies. J Antimicrob Chemother 2019; 74 (10) 3049-3055
    CrossrefPubMedGoogle Scholar
  • 69 Johnson MD, Lewis RE, Dodds Ashley ES. et al. Core recommendations for antifungal stewardship: a statement of the Mycoses Study Group Education and Research Consortium. J Infect Dis 2020; 222 (Suppl. 03) S175-S198
    CrossrefPubMedGoogle Scholar
  • 70 Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi (Basel) 2020; 6 (04) 6
    PubMedGoogle Scholar
  • 71 Astvad KMT, Jørgensen KM, Hare RK, Datcu R, Arendrup MC. Olorofim susceptibility testing of 1,423 Danish mold isolates obtained in 2018-2019 confirms uniform and broad-spectrum activity. Antimicrob Agents Chemother 2020; 65 (01) 65
    PubMedGoogle Scholar
  • 72 Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies. J Antimicrob Chemother 2020; 75 (12) 3582-3585
    CrossrefPubMedGoogle Scholar
  • 73 Singh A, Singh P, Meis JF, Chowdhary A. In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species. J Antimicrob Chemother 2021; dkaa562
    PubMedGoogle Scholar
  • 74 Brand SR, Sobel JD, Nyirjesy P. et al. Randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin Infect Dis 2020; ciaa1204 . doi: 10.1093/cid/ciaa1204
    CrossrefPubMedGoogle Scholar
  • 75 Thompson GR, Soriano A, Skoutelis A. et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis—The STRIVE trial. Clin Infect Dis 2020; ciaa1380 . doi: 10.1093/cid/ciaa1380
    CrossrefPubMedGoogle Scholar
  • 76 Miesel L, Cushion MT, Ashbaugh A, Lopez SR, Ong V. Efficacy of rezafungin in prophylactic mouse models of invasive Candidiasis, Aspergillosis, and Pneumocystis pneumonia. Antimicrob Agents Chemother 2021; 65 (03) e01992-20
    CrossrefPubMedGoogle Scholar